培美曲塞联合卡铂治疗66例非小细胞肺癌的效果观察

Efficacy of Pemetrexed Plus Carboplatin for 66 Cases of Non-small Cell Lung Cancer

目的探究培美曲塞联合卡铂化疗方案对非小细胞肺癌患者的治疗效果。方法随机抽取66例非小细胞癌患者,按照随机抽签单双号,均分为观察组(培美曲塞联合卡铂化疗方案)、对照组(吉西他滨联合卡铂化疗方案)。观察2组的治疗效果和不良反应。结果本次研究中的联合化疗,全组共进行了280个周期,无患者出现不能耐受而退出治疗。2组患者KPS下降与无下降比率无显著差异(P>0.05)。FISHER精确检验,观察组RR、DCR显著高于对照组(P均<0.05)。观察组肿瘤病灶局部复发、转移与对照组无显著差异(P均>0.05),但MPFS显著长于对照组(P=0.003)。观察组血小板减少、血红蛋白减少、中性粒细胞减少、肾功能损害、肝功能损害、腹泻、恶心、呕吐、皮疹等发生率显著低于对照组(P<0.05)。结论培美曲塞联合卡铂化疗方案治疗效果优于吉西他滨联合卡铂,且临床不良反应较轻微、耐受性好,值得推广应用。

Objective To explore the efficacy of pemetrexed plus carboplatin for non-small cell lung cancer.Methods66 patients with non-small cell carcinoma were randomly divided into the observation group（pemetrexed plus carboplatin chemotherapy） and the control group（gemcitabine plus carboplatin chemotherapy）.Curative effects and adverse reactions of the 2groups were observed.Results In the study of the MDT,full set of 280 cycles were conducted,all patients could tolerate the treatment.There had no significant difference in KPS decrease and stable ratio between the 2 groups（P〈0.05）; FISHER＇s exact test showed that RR,DCR in the observation group were significantly higher than those of the control group（P〈0.05）; Local recurrence of tumor lesions and transfer between the 2 groups had no significant difference（P〈0.05）; But MPFS in the observation group was significantly longer than that of the control group（P = 0.003）.Thrombocytopenia,hemoglobin decreased,neutropenia,renal dysfunction,liver dysfunction,diarrhea,nausea,vomiting,and skin rash in the observation group were significantly lower than those of the control group（P〈0.05）.Conclusion Pemetrexed plus carboplatin chemotherapy is more effective than gemcitabine plus carboplatin for non-small cell lung cancer,the clinical adverse reactions is mild,with good tolerance,it is worthy of popularization and application.